Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,676 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L, Lindsay H, Kogiso M, Du Y, Braun FK, Zhang H, Guo L, Zhao S, Injac SG, Baxter PA, Su JM, Xiao S, Erickson SW, Earley EJ, Teicher B, Smith MA, Li XN. Qi L, et al. Among authors: guo l. Lab Invest. 2022 Feb;102(2):185-193. doi: 10.1038/s41374-021-00700-8. Epub 2021 Nov 20. Lab Invest. 2022. PMID: 34802040 Free PMC article.
Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma.
Kogiso M, Qi L, Du Y, Braun FK, Zhang H, Huang LF, Guo L, Huang Y, Teo WY, Lindsay H, Zhao S, Injac SG, Liu Z, Mehta V, Tran D, Li F, Baxter PA, Su JM, Perlaky L, Parsons DW, Chintagumpala M, Adesina A, Song Y, Li XN. Kogiso M, et al. Among authors: guo l. Transl Oncol. 2022 Apr;18:101368. doi: 10.1016/j.tranon.2022.101368. Epub 2022 Feb 16. Transl Oncol. 2022. PMID: 35182954 Free PMC article.
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer.
Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, Tu Y, Zhang X, Qi Y, Jiang Y, Echeverria G, Feng N, Ma X, Giuliani V, Marszalek JR, Heffernan TP, Vellano CP, White JB, Stephan C, Davies PJ, Moulder S, Symmans WF, Chang JT, Piwnica-Worms H. Powell RT, et al. Among authors: guo l. Sci Rep. 2020 Oct 21;10(1):17899. doi: 10.1038/s41598-020-74882-4. Sci Rep. 2020. PMID: 33087803 Free PMC article.
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer.
Powell RT, Rinkenbaugh AL, Guo L, Cai S, Shao J, Zhou X, Zhang X, Jeter-Jones S, Fu C, Qi Y, Baameur Hancock F, White JB, Stephan C, Davies PJ, Moulder S, Symmans WF, Chang JT, Piwnica-Worms H. Powell RT, et al. Among authors: guo l. NPJ Breast Cancer. 2024 May 27;10(1):37. doi: 10.1038/s41523-024-00644-4. NPJ Breast Cancer. 2024. PMID: 38802426 Free PMC article.
p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance.
Zhang J, Tan P, Guo L, Gong J, Ma J, Li J, Lee M, Fang S, Jing J, Johnson G, Sun D, Cao WM, Dashwood R, Han L, Zhou Y, Dong WG, Huang Y. Zhang J, et al. Among authors: guo l. Oncogene. 2019 Mar;38(11):1905-1919. doi: 10.1038/s41388-018-0524-5. Epub 2018 Nov 2. Oncogene. 2019. PMID: 30390073 Free PMC article.
21,676 results
You have reached the last available page of results. Please see the User Guide for more information.